clinical trial · NCT07453888
Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
Dompé Farmaceutici S.p.A·phase3·recruiting·n = 272
Non-Arteritic Anterior Ischemic Optic NeuropathyCenegerminVehicle
brief summary
This is a phase 3, randomized, multicenter, vehicle-controlled, double-masked study to evaluate the efficacy and safety of intranasal cenegermin compared with vehicle control in adult participants with NAION. Approximately 272 participants who meet all eligibility criteria will be randomly assigned in a 1:1 ratio to receive either cenegermin treatment (Group 1) or the vehicle control (Group 2).
started
Jul 1, 2026
primary completion
Sep 1, 2027
completion
Sep 1, 2027
last updated
Sep 10, 2026
official title
Randomized, Multicenter, Vehicle-Controlled, Double-Masked Phase 3 Study to Evaluate the Efficacy and Safety of Intranasal Cenegermin (Recombinant Human Nerve Growth Factor [rhNGF]) in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol